Obesity, the sympathetic nervous system, and essential hypertension

Hypertension

Volumn 19, Issue 1, 1992, Pages I-67-I-77

  Tuck, Michael L ^a  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

Antihypertensive therapy; Essential hypertension; Norepinephrine; Obesity; Sympathetic nervous system

Indexed keywords

ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NORADRENALIN;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; BLOOD VESSEL REACTIVITY; CATECHOLAMINE BLOOD LEVEL; DRUG MECHANISM; ESSENTIAL HYPERTENSION; HUMAN; NEUROGRAPHY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SPECTROSCOPY;

HUMAN; HYPERTENSION; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 0026569450     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.hyp.19.1_suppl.i67     Document Type: Article

References (90)

1. Mark AL: Regulation of sympathetic nerve activity in mild human hypertension. J Hypertent 1990;8(suppl 7):S67–S75
2. Esler M, Gavin L, Jennings G: Increased regional sympathetic nervous activity in human hypertension: Causes and consequences. J Hypertent 1990;8(suppl 7):S53–S57
3. Julius S: The blood pressure seeking properties of the central nervous system. J Hypertent 1988;6:177–185
4. Goldstein D, Kopin IJ: The autonomic nervous system and catecholamines in normal blood pressure control and in hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. New York, Raven Press, Publishers, 1990, pp 711–737
5. De Champlain J: Pre- and postsynaptic adrenergic dysfunctions in hypertension. J Hypertent 1990;8(supp1 7):S77–S85
6. Tuck ML: The sympathetic nervous system in essential hypertension. Am J Cardiol 1986;112:877–886
7. Goldstein DS: Plasma catecholamines in essential hypertension: An analytical review. Hypertension 1983;5:86–96
8. Esler M, Jennings G, Korner P, Blomberg P, Burke F, Willett I, Leonard PW: Total, and organ-specific, noradrenaline and plasma kinetics in essential hypertension. Clin Exp Hypertens (A) 1984;6:507–516
9. Tuck ML, Stem N, Sowers JR: Enhanced 24-hour norepinephrine and renin secretion in young patients with essential hypertension: Relation with circadian pattern of arterial blood pressure. Am J Cardiol 1985;55:112–118
10. Egan B, Panis R, Hinderliter A, Schork N, Julius S: Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. J Clin invest 1987;80:812–817
11. Esler M, Julius S, Zweifler A: Mild high-renin essential hypertension: A neurogenic form of human hypertension? N Engt J Med 1977;296:405–411
12. Kakembo GHK: The factors affecting inter-individual differences in response to bethanidine (dissertation). Bonn, FRG, Medizinischen Universitatsklinik, 1982
13. Myers MG, deChamplain J: Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension. Hypertension 1983;5:591–597
14. Hulthen UL Bolli P, Amamt FW, Kiowski W, Buhler FR: Verapamil-induced vasodilation is enhanced in essential hypertension. J Cardiovasc Pharmacol 1982;4(suppl 3):S313–S321
15. Erne P, Buhler FR, Affolter H, Burgisser E: Excitatory and inhibitory modulation of intracellular free Ca++ in human platelets by hormones and drugs. Eur J Pharmacol 1983;91: 331–339
16. Goldstein DS, Levinson PD, Zimlichman R, Pitterman A, Stull R, Keiser HR: Clonidine suppression testing in essential hypenension. Ann Intern Med 1985;102:42–48
17. Tomioka H, Miura Y, Adachi M, Kimura S, Nezu M, Yoshi-naga K: The significance of sympathetic nerve activity in the pathogenesis of essential hypertension, with special reference to the effects of centrally acting sympatholyrics on plasma norepinephrine concentration and hemodynamic variables. Nippon Naibunpi Cakkai Zasshi 1982;71:1103–1109
18. Esler M, Jennings G, Korner P, Willett I, Dudley F, Haking G, Aderson W, Lambert G: Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988;11:3–20
19. Esler M, Jennings G, Btviano B, Lambert G, Hasking G: Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1985;8(suppl 5):539–544
20. Korner PI: Integrative neural cardiovascular control. Physiol Rev 1971;51:312–367
21. Hollenberg NK, Snador T: Vasomolion of renal blood flow in essential hypertension. Hypertension 1984;6:579–584
22. Goldstein DS, Eisenhofer G, Garty M, Folio CJ, Stull R, Brush JE Jr, Sax FL, Keiser HR, Kopin IJ: implications of plasma levels of catechols in the evaluation of sympatho-adrenomedullary function. Am J Hypertens 1989;2:S133–S139
23. Wallin BG, Delius W, Hagbarth K-E: Comparison of sympathetic nerve activity in normotensrve and hypertensive subjects. Circ Res 1973;33:9–21
24. Anderson EA, Sinkey CA, Lawton WJ, Mark AL: Elevated sympathetic nerve activity in borderline hypertensive humans: Evidence from direct intraneuronal recordings. Hypertension 1989;14:177–183
25. Yamada Y, Miyajima E, Tochikubo O, Matsukawa AT, Ishii M: Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989;13:870–877
26. Akselrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ: Hemodynamic regulation: Investigation by spectra] analysis. Am J Physiol 1985;249:H867–H875
27. Guzzetti S, Piccaluga E, Casati R, Cerutti S, Lombardi F, Pagani M, Malliani A: Sympathetic predominance in essential hypertension: A study employing spectral analysis of heart rate variability. J Hypertens 1988;6:711–717
28. Phillip T, Distler A, Cordes U: Sympathetic nervous system and blood pressure control in essential hypertension. Lancet 1978;2:959–967
29. Falkner B, Onesti G, Angelakos ET, Fernandes M, Langman C: Cardiovascular response to mental stress in normal adolescents with hypertensive parents. Hypertension 1979;1:23–30
30. Doyle AE, Fraser JRE: Essential hypertension and inheritance of vascular reactivity. Lancet 1961;2:509–516
31. Hollenberg NK, Williams GH, Adams DF: Essential hypertension: Abnormal renal vascular responses to mild psychological stimulus. Hypertension 1981;3:11–19
32. Mancia G: Methods for assessing blood pressure values in humans. Hypertension 1983;5(suppl III):III-5–III-13
33. Majewski H, Rand MJ: Adrenaline mediated hypertension: A clue to the antihypertensive effect of bet a-adrenoreceptor blocking drugs. Trends Pharmacol Set 1981;2:24–36
34. Brown MJ: Is epinephrine the cause of essential hypertension? in Edwards CRW, Carey RM (eds): Essential Hypertension as an Endocrine Disease. Toronto/London, Butterworth & Co, Ltd, 1985, p 40
35. Floras JS, Aylward PE, Victor RG, Mark AL, Abboud FM: Epinephrine facilitates neurogenic vasoconstriction in humans. J Clin Invest 1988;81:1265–1274
36. Floras JS, Aylward PE, Mark AL, Abboud FM: Adrenaline facilitates neurogenic vasoconstriction in borderline hypertensive subjects. J Hypertens 1990;8:443–448
37. Snider SR, Kuchel O: Dopamine: An important neurohormone of the sympatho-adrenal system: Significance of the increased peripheral dopamine release for the human stress response and hypertension. Endocr Rev 1983;4:291–305
38. Sowers JR, Tuck ML, Golub MS, Sollars E: Dopaminergic control of aldosterone secretion is independent of alteration in renin secretion. Endocrinology 1980;137:937–946
39. Landsberg L: Diet, obesity and hypertension: An hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;236:1081–1090
40. Landsberg L, Krieger DR: Obesity, metabolism, and the sympathetic nervous system. Am J Hypertens 1989;2(suppl 2):125S-132S
41. Tuck ML, Sowers JR, Domfield L, Whitfield L, Maxwell M: Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinol (Copenh) 1983;102:252–257
42. Sowers JR, Whitfield LA, Catania RA, Stern N, Tuck ML, Dornfeld L, Maxwell M: Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Melab 1982;54:1181–1187
43. Maxwell MH, Heber D, Walts AU, Tuck ML, Schroth P, Domfeld LP: Dynamic changes in insulin and catecholamines during weight loss in obesity-associated hypertension. Int J Obes (in press)
44. Reisin E, Frohlich ED, Messerli FH, Dreslinski GR, Gunn FG, Jones MM, Batson HM Jr: Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med 1983;98:315–319
45. DeHaven J, Sherwin R, Handler R, Felig P: Nitrogen and sodium balance and sympathetic-nervous-system activity in obese subjects treated with a low-calorie protein or mixed diet. N Engl J Med 1980,302:477–482
46. Peterson HR, Rothschild M, Weinberg CR, Fell RD, MacLeish KR, Pfeifer MA: Body fat and the activity of the autonomic nervous system. N Engl J Med 1988;318:1077–1083
47. Bray GA: Integration of energy intake and expenditure in animals and man: The autonomic and adrenal hypothesis. Clin Endocrinol Metab 1984;13:521–546
48. Schwartz RS, Haller JB, Bierman EL: Reduced thermic effect of feeding in obesity: Role of norepinephrine. Metabolism 1983;32:114–117
49. Swaminathan R, Anderson E, Dean H, Wales JK; Metabolic response to insulin induced hypoglycaemia in lean and obese subjects. Harm Metab Res 1986;18:45–48
50. Gustafson AB, Kalkhoff RK: Influence of sex and obesity on plasma catecholamine response to isometric exercise. J Clin Endocrinol Metab 1982;55:703–708
51. Jung RT, Shetty PS, James WPT, Barrand MA, Callingham BA: Reduced thermogenesis in obesity. Nature 1979;279: 322–323
52. Bray GA: Obesity: A disease of nutrient or energy balance? Nutr Rev 1987;45:33–43
53. Bray GA: Autonomic and endocrine factors in the regulation of energy balance. Fed Proc 1986;45:1404–1410
54. Sakaguchi T, Takahashi M, Bray GA: Diurnal changes in sympathetic activity. J Clin Invest 1988;82:282–286
55. O’Dea K, Esler M, Leonard P, Stockigt JR, Nestel P: Noradrenaline turnover during under- and over-eating in normal weight subjects. Metabolism 1982;31:896–899
56. Tuck ML: Endocrine factors in obesity hypertension, in Edwards CRW, Carey RM (eds): Essential Hypertension as an Endocrine Disease. Toronto/London, Butterworth & Co, Ltd, 1985, pp 333–367
57. Domfeld LP, Maxwell MH, Walts AU, Schroth P, Tuck ML: Obesity and hypertension: Long-term effects of weight reduction on blood pressure. Int J Obes 1985;9:381–389
58. Weinsier R, Liu C, Norris D, et al: The relative effects of calorie leslricliun and weight loss on blood pressure in moderately hypertensive obese women (abstract). Clin Res 1987; 35:781A
59. Jung RT, Shetty PS, Barrand M, Callingham BA, James WPT: Rule of catecholamines in hypotensive response to dieting. Br Med J 1979;1:12–13
60. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M: The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989;321:580–585
61. Reisin E, Frohlich ED, Messerli FH, Dreslinski GR, Dunn FG, Jones MM, Batson HM Jr: Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med 1983;98:315–319
62. Tuck ML, Sowers J, Domfeld L, Kledzik G, Maxwell M: The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981;304:930–933
63. Messerli FH, Sundgaard-Riise K, Reisin E, Dreslinski GR, Dunn FG, Frohlich ED: Disparate cardiovascular effects of obesity and essential hypertension. Am J Med 1983;74:808–822
64. DeHaven J, Sherwin R, Hendler R, Felig P: Nitrogen and sodium balance and sympathetic-nervous-system activity in obese subjects treated with a low-calorie protein or mixed diet. N Engl J Med 1980;302:477–482
65. Gross HA, Lake CR, Ebert MH, Ziegler MG, Kopin U: Catecholamine metabolism in primary anorexia nervosa. J Clin Endocrinol Metab 1979;49:805–809
66. Ramirez A, Fletes L, Mizrahi L, Parra A: Daily urinary catecholamine profile in marasmus and kwashiorkor. Am J Out Mur 1978;31:41–45
67. Scheen AJ, Fossion A, Scheen-Lavigne M, Luyckx AS, Lefebvre PJ: Sympatho-adrenal activity and tissue sensitivity to catecholamines of obese subjects before and after protein-supplemented fasting. J Obes Weight Regal 1984;3:15–34
68. Havlik RJ, Hubert HB, Fabsitz RR, Feinleib M: Weight and hypertension. Ann Intern Med 1983;98:855–859
69. Eliahou HE, Iaina A, Gaon T, Schochat J, Modan M: Body weight reduction necessary to attain normotension in the overweight hypertensive patient. Int J Obes 1981;5:157–163
70. Wassertheil-Smoller S, Blaufox D, Oberman A, Davis BR, Swenctonis C, Knerr MO, Hawkins CM, Langford HG: Effectof anti hypertensives on sexual function and quality of life The TAIM Study Ann Intern Med 1991,114 613–620
71. Izzo JL Sympalho-adrenal activity, catecholamines, and the pathogenesis of vasculopathic hypertensive target-organ damage Am J Hypertens 1989;2 305S–312S
72. Rosenman RH Results of the mult ice nter anti hypertensive treatment trials Therapeutic implications and the role of the sympathetic nervous system Am J Hypertens 1989,2 313S–338S
73. Cohn JN Sympathetic nervous system activity and the heart Am J Hypertens 1989,2 353S–356S
74. MacMahon SW, Cutler JA, Furberg CD, Payne GH The effect of drug treatment for hypertension on morbidity and mortality from cardiovascular disease A review of randomized controlled trials Prog Canhovasc Dis 1986,2(suppl) 99–118
75. Dzau VJ, Gibbons GH Cell biology of vascular hypertrophy in systemic hypertension. Am J Candtol 1988,62 30–35
76. Sen S Regression of cardiac hypertrophy Experimental animal model Am J Med 1983,75 87–93
77. Lake CR, Ziegler MG, Coleman MD, Kopin IJ Hydrochlo-rothiazide-mduced sympathetic hyperactivity in hypertensive patients Clsn Pharmacol Ther 1979,26 428–432
78. Reisin E, Weed SG Diuretics A rational pharmacological approach for the treatment of obese hypertensives (abstract) Hypertension 1991,17 405
79. Pollare T, Lithell H, Berne C A comparison of the effects of hydrochlorothiazide and captopnl on glucose and lipid metabolism m patients with hypertension N Engl J Med 1989,321 868–873
80. Vlachakis ND, Alcdort L Hypertension and propranolol therapy Effect on blood pressure, plasma catecholamines and platelet aggregation Am J Cardiol 1980,45 321–325
81. Sundlof G, Wallin BG, Stromgren E, Nerhed C Acute effects of metoprolol on muscle sympathetic activity in hypertensive humans Hypertension 1983,5 749–757
82. MacMahon SW, MacDonald GJ, Bernstein L, Andrews G, Blacken RB Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients Lancet 1985,1 1233–1236
83. Pollare T, Lithell H, Selinus I, Berne C Sensitivity to insulin during treatment with atenolol and metoprolol A randomized double-blind study of the effects on carbohydrate and lipoprotein metabolism in hypertensive patients Br Med J [Qin Res] 1989,298 1152–1157
84. Eklund B, Hjemdahl P, Seidman P, Atterhog JH Effects of prazosin on hemodynamics and sym pat ho-ad renal activity in hypertensive patients J Cardtovasc Pharmacol 1983,5 384–396
85. Pollare T, Lithell H, Selinus I, Beme C Application of prazosin is associated with an increase in insulin sensitivity in obese patients with hypertension Diabetologia 1988,31 415–420
86. Crozier IG, Teoh R, Kay R, Nicholls MG Sympathetic nervous system during converting enzyme inhibition Am J Med 1989,87 6B-29S–6B-32S
87. Fouad-Tarazi FM Left ventricular diastolic dysfunction and cardiovascular regulation in hypertension Am J Med 1989;87 6B-42S–6B-44S
88. Marie M, Leblanc H, Suarez L, Guyenne TT, Menard J, Passa P Convert mg enzyme inhibition and kidney function in nor-motensive diabetic patients with persistent microalbuminuria Br Med J [Clin Res] 1987,294 1448–1452
89. Cody RJ, Kubo SH, Ryman KS, Shaknovich A, Laragh JH Systemic and pulmonary hemodynamic responses to nicardipine during graded ergometnc exerase in patients with moderate to severe essential hypertension J Am Coll Cardiol 1987,10 647–654
90. Tuck ML, Bravo EL, Krakoff LR, Fnedman CP, and the Modem Approach to the Treatment of Hypertension Study Group Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension Results of a multicenter trial Am J Hypertens 1990,3 333S–341S